Physician profile
Vinod Mohan
NPI 1326351594
$1,589.27
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.07 · 2021: $199 · 2022: $1,174 · 2023: $146 · 2024: $40.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $186.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $492.45 | 2022 | |
| Abbvie INC. | $235.65 | 2021-2023 | |
| Novo Nordisk INC | $125.35 | 2022-2024 | Ozempic, Rybelsus |
| Amgen INC. | $109.90 | 2021-2022 | |
| Lilly USA, LLC | $80.33 | 2022-2023 | Trulicity, Mounjaro |
| Merck Sharp & Dohme LLC | $80.09 | 2020-2022 | |
| Pfizer INC. | $71.71 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $62.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $47.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $44.77 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $44.71 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.14 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $31.92 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $26.99 | 2021 | |
| Janssen Biotech, INC. | $23.04 | 2023 | Symtuza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $22.71 | 2022 | |
| Glaxosmithkline, LLC. | $21.29 | 2023 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $14.59 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.